Cannabinoid Translational Science’s Post

We can't wait! Please consider attending the 'De-Risking Secondary Pharmacology Mediated Adverse Effects as a Path to Develop Safer Medicines' session which we are sponsoring: https://lnkd.in/ds5JDFby It includes talks by some great scientists: Dr. Jordi Mestres, IMIM Hospital del Mar Research Institute 'Translational Safety meets Pharmacovigilance' Dr. Rebecca Racz, PharmD, FDA 'Analysis of Secondary Pharmacology Submissions to the US' Dr. Sonia Roberts, Roche 'Translational Pharmacology Case Studies: Intricacies of predicting patient risk from in vitro secondary pharmacology data' Dr. Friedemann Schmidt, Sanofi-Aventis Deutschland GmbH 'An IQ-DruSafe secondary pharmacology industry database analysis of current practices, experiences and recommendations for the future' Dr. Jean-Pierre Valentin, UCB BioPharma 'Challenges, opportunities and state of the art considerations for in vitro and in silico secondary pharmacology profiling' #EPHAR2024 #pharmacology #pharmaceuticals #toxicology #PatientSafety

🌟 Excited to Share My Learning Journey! 🌟 I had the wonderful opportunity to attend an online workshop on Molecular Docking Techniques👩💻, organized by Discovery Boulevard. This workshop provided valuable insights into the theoretical and practical aspects of molecular docking, highlighting its importance in drug discovery and research. The sessions were highly informative and have enhanced my understanding of computational approaches in pharmacology. I’m grateful to the organizers for delivering such an engaging and informative session. It has further fueled my passion for pharmacology and clinical research. Looking forward to applying these skills in my journey ahead! #MolecularDocking #WorkshopExperience #DrugDiscovery #ClinicalResearch

Symposium on neutron scattering highlighted possibilities to advance drug discovery! The IPDD symposium on neutron scattering in May aimed to highlight ongoing research and possibilities with neutron scattering in drug design, discovery and formulation, and gathered around 25 researchers from Lund and Copenhagen as well as international speakers joining via zoom. Organisers Raminta Venskutonytė from the Medical Faculty at Lund University, and Zoë Fisher from ESS, reflect on the outcomes of the event. – The symposium provided good opportunities for participants to talk and network, with ample opportunities for in-depth conversations, says Raminta Venskutonytė, associate researcher at Medical Structural Biology, Lund University, and leader of the Structure-based Drug Design (SBDD) working group. – It was great to be able to highlight how neutrons fill an important gap in the drug discovery pipeline, and how they can be used as part of drug target validation, and drug discovery, shedding light on how ligands or drugs interact with their target. Finally, neutrons also have an application in optimizing drug formulation for efficient drug delivery, says Zoë Fisher. Zoë Fisher Vito Foderà Karin Lindkvist Raminta Venskutonytė https://lnkd.in/dtt-hf7F

Today is “World Parkinson’s Day” and EDELRIS is pleased to share its latest contribution to Parkinson’s drug discovery: In 1817 Dr. James Parkinson published “An Essay on the Shaking Palsy” which first recognized Parkinson’s as a medical condition. April 11th is “World Parkinson’s Day” in commemoration of the birthday of Dr. James Parkinson, but also to raise awareness of Parkinson’s. Since 1817 a lot of research has been done to alleviate and treat this handicapping condition, but there is still a high medical need. Today, Edelris' Medicinal Chemistry Team is excited and humbled to announce that our research efforts have contributed to the selection of a preclinical candidate for Parkinson's. Cross-fertilizing efforts with our project partners ARGOBIO, GeneCode, University of Helsinki, and Evotec, we reached a significant milestone on a challenging medicinal chemistry project for an innovative therapeutic approach to Parkinson’s disease. Edelris’ team of medicinal chemists efficiently managed to solve ADME liabilities of hit compounds, to deliver novel lead series protected by two patent applications. This two-year-long medicinal chemistry collaboration allows the project team to select a preclinical candidate with neurotrophic and neuroprotective effects on human dopaminergic neurons. For Edelris, contributing as medicinal- and analytical chemistry experts to this challenging Parkinson’s discovery project within a network of partners is second nature!  https://lnkd.in/eyu-mmdP https://lnkd.in/gJF5yBbn #drugdicovery #medicinalchemistry #parkinson’s #innovation

07 de Novembro!! #Webinar #Citometriadefluxo Cytometry in Drug Discovery: An Introduction to Regulation, Standardization, and Productivity. with Michelle Campbell-Ryan, Regional Flow Cytometry Application Specialist, Bio-Rad. Flow cytometry is increasingly being used in the field of drug discovery. It is a technique that many researchers learn whilst studying in academia. But for any researcher hoping to transition from academia to the commercial sector, there are significant differences in its application to be aware of, especially relating to regulation and the increased need for standardization. https://lnkd.in/dmm-5ZED

"... we are witnessing a paradigm shift in drug testing and development, with a focus directed towards the use of primary cells and organoids..." Nora Fekete-Drimusz, PhD, head of biology at ARRALYZE. I recently spoke with Nora about the transformative impact of single-cell analysis on drug development and we discussed how the company's multifunctional single-cell platform supports professionals in this field. #singlecellanalysis #drugdiscovery #livecellimaging

𝗖𝗘𝗟𝗟𝗟𝗜𝗠𝗔 𝗧𝗔𝗟𝗞𝗦 𝗩 𝗚𝘂𝗮𝗿𝗱𝗶𝗮𝗻𝘀 𝗼𝗳 𝗵𝗲𝗮𝗹𝘁𝗵: 𝗧𝗵𝗲 𝘀𝘁𝘂𝗱𝘆 𝗼𝗳 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝘀 𝗶𝗻 𝗲𝗮𝗿𝗹𝘆 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. https://lnkd.in/eBwc5MqX 🏥 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗼𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝘀 𝗵𝗮𝘀 𝗹𝗲𝗱 𝘁𝗼 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀 𝗶𝗻 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘄𝗶𝘁𝗵 𝗧𝗵𝗼𝗺𝗮𝘀 𝗠𝘂̈𝗹𝗹𝗲𝗿 𝗮𝗻𝗱 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝘁𝗿𝗲𝗻𝗱𝘀 𝗶𝗻 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗹𝗼𝗴𝘆. Whether you're an experienced researcher, a biology student, or simply curious about the latest advances in science and medicine, this webinar promises to inspire and inform. Don't miss this opportunity to gain insights from a leading expert and explore the future of ion channel research. Register now and be part of this exciting event that bridges science and innovation! https://lnkd.in/e_JMdfiE 𝘛𝘩𝘦 𝘤𝘰𝘯𝘷𝘦𝘳𝘴𝘢𝘵𝘪𝘰𝘯 will be 𝘪𝘯 𝘎𝘦𝘳𝘮𝘢𝘯 𝘸𝘪𝘵𝘩 𝘴𝘪𝘮𝘶𝘭𝘵𝘢𝘯𝘦𝘰𝘶𝘴 𝘌𝘯𝘨𝘭𝘪𝘴𝘩 𝘵𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘪𝘰𝘯 𝘰𝘯 𝘢 𝘴𝘦𝘤𝘰𝘯𝘥 𝘢𝘶𝘥𝘪𝘰 𝘵𝘳𝘢𝘤𝘬. #cellbiology #drugdiscovery #research #healthcare @CELLIMA

In this webinar students will interact and build networks with PhD-level, postdoctoral and professional panelists on graduate school applications, program selection criteria, and relevant research areas in the pharmacology field. Register here: https://bit.ly/3nGodfw.

Improving physiological relevance in neurological disease drug development In this case study, hear from Elise LV Malavasi, Ph.D., a Principal Scientist at leading contract research organisation Concept Life Sciences. The interview highlights their need to develop assays that are amenable to long term use to support their clients with drug development, and how bit.bio’s deterministically programmed ioMicroglia have helped them develop assays with increased physiological relevance and consistency, towards this goal. In this case study you will learn: - How Concept Life Sciences seek to develop assays proving drug candidate efficacy with human iPSC-derived microglia. - How ioMicroglia from bit.bio offered Concept Life Sciences functional cells with low inter-lot variability, ensuring consistent assay performance, facilitating large scale screening studies. - How Concept Life Science’s initial challenges integrating this new cell type into their workflows were overcome by support from the bit.bio team, ensuring they could easily develop assays using these cells. Download Case Study https://lnkd.in/ePNFw9dX Brought to you by bit.bio  #DrugDevelopment #DrugDiscovery #LifeSciences

At Bracken, we know that a personalized approach is key when it comes to patient engagement, and we make sure to bring that to the table with every organization we work with. Jim Gilligan, MSIB, PhD, Bracken Managing Partner, explains what this means: "[Patient engagement] is one of the practical things Bracken brings to programs that goes a little bit beyond just the molecular biology or the pharmacology—we bring [a personalized] perspective to help different organizations with a tremendous concept, transforming into something that could have commercial reality." #PatientEngagement #Pharma